Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.

ABSTRACT:

Background and objective

Methylating agents are effective chemotherapy agents for Hodgkin lymphoma, but are associated with the development of second primary cancers. Cytotoxicity of methylating agents is mediated primarily by the DNA mismatch repair (MMR) system. Loss of MLH1, a major component of DNA MMR, results in tolerance to the cytotoxic effects of methylating agents and persistence of mutagenised cells at high risk of malignant transformation. We hypothesised that a common substitution in the basal promoter of MLH1 (position -93, rs1800734) modifies the risk of cancer after methylating chemotherapy.

Methods

133 patients who developed cancer following chemotherapy and/or radiotherapy (n = 133), 420 patients diagnosed with de novo myeloid leukaemia, 242 patients diagno

SUBMITTER: Worrillow LJ 

PROVIDER: S-EPMC4022773 | biostudies-literature | 2008 Mar

REPOSITORIES: biostudies-literature